



Utilizing UL97 Resistant Codon Specificities to Guide Pharmacotherapy Treatment Decisions in Resistant Cytomegalovirus Infections

Angela Q Maldonado^{1*}, David B Leiser² and Tomefa E Asempa³

¹Department of Transplant Surgery, Vidant Medical Center, Greenville, NC 27834, USA

²Department of Transplant Surgery, East Carolina University, Greenville, NC 27858, USA

³Department of Pharmacy, Vidant Medical Center, Greenville, NC 27834, USA

***Corresponding author:** Angela Q Maldonado, Department of Transplant Surgery, Vidant Medical Center, Greenville, NC 27834, USA, E-mail: angela.maldonado@vidanthealth.com

Received date: February 28, 2018; **Accepted date:** March 22, 2018; **Published date:** March 26, 2018

Copyright: © 2018 Maldonado AQ, et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

(ANC) > 500 was necessary. However, this exacerbated the patient's sickle cell disease causing hip and bone pain. A transition to VGCV 900 mg twice daily for the maintenance phase of treatment was

differ in their cellular activation, which lends itself to different levels of

